Type of support |
Approvals 2001-2023 (US$)(26 Dec 2018) |
Commitments 2001-2023 (US$)(26 Dec 2018) |
Disbursements 2000-2018 (US$)(26 Dec 2018) |
% Disbursed(26 Dec 2018) |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|
Total |
$235,639,609 |
$260,417,109 |
$219,651,009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Support (CASHSUPP) |
$145,000 |
$170,000 |
$145,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cold Chain Equipment Optimisation Platform (CCEOP) |
$3,802,899 |
$3,802,899 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 1) |
$4,978,500 |
$4,978,500 |
$4,978,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 2) |
$4,436,347 |
$4,436,347 |
$4,436,347 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 3) |
$5,040,000 |
$11,760,000 |
$2,800,000 |
56% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV Demo (NVS) |
$189,506 |
$189,506 |
$190,622 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immunisation services support (ISS) |
$9,705,605 |
$9,705,605 |
$9,705,605 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection Safety Devices (NVS) |
$1,003,479 |
$1,295,979 |
$620,700 |
62% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection safety support (INS) |
$931,560 |
$931,560 |
$931,560 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IPV (NVS) |
$2,712,179 |
$2,712,179 |
$842,072 |
31% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Measles (NVS) |
$1,247,229 |
$1,247,229 |
$1,234,922 |
99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Measles-Rubella (NVS) |
$6,000,965 |
$6,000,965 |
$6,000,965 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A (NVS) |
$1,548,371 |
$2,078,871 |
$1,626,072 |
105% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A - mini catch-up campaign (NVS) |
$3,134,671 |
$3,134,671 |
$3,134,671 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A - mini catch-up op.costs (OPC) |
$2,571,802 |
$2,571,802 |
$2,571,802 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MR - Operational costs (OPC) |
$4,925,847 |
$4,925,847 |
$4,925,847 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Penta (NVS) |
$65,397,939 |
$66,689,939 |
$64,359,150 |
98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pneumo (NVS) |
$63,045,663 |
$70,665,663 |
$68,403,179 |
108% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product Switch Grant (PSG) |
$194,286 |
$194,286 |
$194,285 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotavirus (NVS) |
$51,069,267 |
$59,366,767 |
$38,991,216 |
76% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccine Introduction Grant (VIG) |
$3,558,494 |
$3,558,494 |
$3,558,494 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format